Intellia Therapeutics, Inc.

Health Care
Biotechnology: In Vitro & In Vivo Diagnostic Substances
www.intelliatx.com

Moat Score

Market Cap $1.44B
PE -3
Debt $NaN
Cash $120.50M
EV $NaN
FCF -$363.06M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$522.28M
EBIT	-$537.71M
ROE	-54%
ROA	-46%
FCF	-$363.06M
Equity	$962.62M
Growth Stability	1
PE	-2.76
PB	1.5
P/FCF	-3.96
P/S	33.4
Price/Cash	0.08
Net Margins	-867%
Op. Margins	-1K%
Sales Growth YoY	-24%
Sales Growth QoQ	31%
Sales CAGR	17%
FCF CAGR	-0%
Equity CAGR	37%

Earnings Growth YoY	11%
Earnings Growth QoQ	-8%
Sales CAGR 5Y	-0%
Equity CAGR 5Y	34%
Earnings CAGR 3Y	6%
Sales CAGR 3Y	6%
Equity CAGR 3Y	1%
Market Cap	$1.44B
Revenue	$43.09M
Assets	$1.17B
Cash	$120.50M
Shares Outstanding	97.78M
Moat Score	1%
Working Capital	605.22M
Current Ratio	6.73
Shares Growth 3y	13%
Equity Growth QoQ	-1%
Equity Growth YoY	-7%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Intellia Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

SEC Filings

Direct access to Intellia Therapeutics, Inc. (NTLA) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Intellia Therapeutics, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Intellia Therapeutics, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Intellia Therapeutics, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Intellia Therapeutics, Inc..

Years

Calculation mode

= -$3.6B

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	-$363M	-$363M	-$363M	-$363M	-$363M	-$363M	-$363M	-$362M	-$362M	-$362M	-$362M	-$3.6B
DCF		-$330M	-$300M	-$273M	-$248M	-$225M	-$205M	-$186M	-$169M	-$154M	-$140M	-$1.4B
Value	-$3.6B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Net Margins	-205%	-192%	-259%	-280%	-231%	-231%	-810%	-910%	-1K%	-867%
ROA	-16%	-11%	-18%	-26%	-32%	-20%	-21%	-30%	-40%	-46%
ROE	58%	-15%	-22%	-31%	-37%	-25%	-26%	-38%	-46%	-54%

Bad Net Margins (-866.88%)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Debt over FCF	-	-	-	-	-	-	-	-	-	-
Debt over Equity	-	-	-	-	-	-	-	-	-	-
Growth Stability	-	-	-	-	-	-	-	-	-	1

Neutral Debt/FCF ratio (-)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Neutral Debt/Equity ratio (-)

The company has a balance between equity and debt that is not too good nor too bad.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	CAGR 5Y
Revenue YoY growth	-	173%	58%	17%	42%	35%	-43%	58%	-30%	-0%
Earnings YoY growth	-	155%	114%	26%	17%	35%	100%	77%	1%	-
Equity YoY growth	-	-1K%	43%	-8%	-3%	95%	97%	19%	-15%	34%
FCF YoY growth	-	-794%	-352%	-10%	63%	-51%	344%	46%	18%	-